

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/08243 A1

(51) International Patent Classification⁷:
C07J 5/00, 31/00, 3/00

(74) Agent: **WALKER, Ralph, Francis**; Corporate Intellectual Property, GlaxoSmithKline, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(21) International Application Number: PCT/GB01/03289

(22) International Filing Date: 20 July 2001 (20.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0017988.7 21 July 2000 (21.07.2000) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALBINSON, Frederick, David** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **COOTE, Steven, John** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **ROBINSON, John, Malcolm** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: OXIDATION PROCESS FOR PREPARING THE INTERMEDIATE 6.ALPHA.,9.ALPHA.-DIFLUORO-11.BETA.,17.ALPHA.-DIHYDROXY-16.ALPHA.-METHYL-ANDROST-1,4-DIEN-3-ONE 17.BETA.-CARBOXYLIC ACID




(57) Abstract: The present invention relates *inter alia* to a novel oxidation process for the synthesis of a known intermediate, useful in the preparation of anti-inflammatory steroids, the known intermediate being of formula (I).

WO 02/08243 A1

OXIDATION PROCESS FOR PREPARING THE INTERMEDIATE 6.ALPHA., 9.ALPHA.-DIFLUORO-11.BETA., 17.ALPHA.-DIHYDROXY-16.ALPHA.-METHYL-ANDROST-1, 4-DIEN-3-ONE 17.BETA.-CARBOXYLIC ACID


The present invention relates to a novel process for the synthesis of a known intermediate, useful in the preparation of anti-inflammatory steroids. There is also provided a new physical form of the intermediate which has improved handling properties

6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-17 α -propionyloxy-3-oxoandrosta-1, 4-diene-17 β -carbothioic acid, S-fluoromethyl ester (Formula A) was first described as an anti-inflammatory steroid by US Patent No. 4,335,121. This compound is also known by the generic name of fluticasone propionate and has since become widely known as a highly effective steroid in the treatment of inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD).



Additionally, 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester (Formula B) was described in WO 97/24365 as a class of hydrolysable steroids with lactone derivatives. This compound possesses useful anti-inflammatory activity whilst having little or no systemic activity.

2



Currently there is considerable interest in compounds of formula (A) and (B) as anti-inflammatory and anti-allergic compounds in the treatment of asthma and other inflammatory diseases.


5

US 4,335,121 and WO 97/24365 describe preparations of fluticasone propionate and 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester, respectively which utilise a common starting material, namely 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -hydroxy-androsta-1,4-diene-17 β -carboxylic acid (Formula I). However, this hydroxy acid androstane derivative compound is an extremely costly starting material for preparing quantities of steroids of formulae (A) and (B).

10

15

Thus, according to a first aspect of the present invention we provide a novel process for the preparation of a compound of formula (I) which comprises the following step:



wherein step (a) comprises oxidation of a solution containing the compound of formula (II).

5 Preferably, step (a) will be performed in the presence of a solvent comprising methanol, water, tetrahydrofuran, dioxan or diethylene glycol dimethylether. For example, so as to enhance yield and throughput, preferred solvents are methanol, water or tetrahydrofuran, and more preferably are water or tetrahydrofuran, especially water and tetrahydrofuran as solvent. Dioxan and
10 diethylene glycol dimethylether are also preferred solvents which may optionally (and preferably) be employed together with water.

Preferably, the solvent will be present in an amount of between 3 and 10vol relative to the amount of the starting material (1wt.), more preferably between 4
15 and 6 vol., especially 5 vol.

If desired, the solution containing the compound of formula (II) may be cooled prior to oxidation eg. to a temperature less than approximately 10°C.

20 Preferably the oxidising agent is present in an amount of 1-9 molar equivalents relative to the amount of the starting material. For example, when a 50% w/w aqueous solution of periodic acid is employed, the oxidising agent may be present in an amount of between 1.1 and 10wt. relative to the amount of the starting material (1wt.), more preferably between 1.1 and 3wt., especially 1.3wt.

25 Preferably, the oxidation step will comprise the use of a chemical oxidising agent. More preferably, the oxidising agent will be periodic acid or iodic acid or a salt thereof. Most preferably, the oxidising agent will be periodic acid or sodium periodate, especially periodic acid. Alternatively (or in addition), it will also be
30 appreciated that the oxidation step may comprise any suitable oxidation

reaction, eg. one which utilises air and/or oxygen. When the oxidation reaction utilises air and/or oxygen, the solvent used in said reaction will preferably be methanol.

- 5 Preferably, step (a) will involve incubating the reagents at room temperature or a little warmer, say around 25 °C eg for 2 hours.

The compound of formula (I) may be isolated by crystallisation from the reaction mixture by addition of an anti-solvent. A suitable anti-solvent for compound of
10 formula (I) is water. Surprisingly we have discovered that it is highly desirable to control the conditions under which the compound of formula (I) is precipitated by addition of anti-solvent eg water. When the crystallisation is performed using chilled water (eg water/ice mixture at a temperature of 0-5 °C) although better anti-solvent properties may be expected we have found that the crystalline
15 product produced is very voluminous, resembles a soft gel and is very difficult to filter. Without being limited by theory we believe that this low density product contains a large amount of solvated solvent within the crystal lattice. By contrast when conditions of around 10 °C or higher are used (eg around ambient temperature) a granular product of a sand like consistency which is very easily
20 filtered is produced. Under these conditions, crystallisation typically commences after around 1 hour and is typically completed within a few hours (eg 2 hours). Without being limited by theory we believe that this granular product contains little or no of solvated solvent within the crystal lattice.

- 25 As a further aspect of the invention we provide a process for preparing a compound of formula (I) which comprises the steps of
(a) oxidation of a solution containing the compound of formula (II) followed by
(b) precipitation of the compound of formula (I) in crystalline form from the reaction mixture by addition of an anti-solvent under temperature conditions
30 of around 10 °C or higher.


Preferably the anti-solvent is water. Preferably the temperature of step (b) is ambient temperature (eg around 18-22 °C) or higher (eg up to 40 °C).

5 We also provide as an aspect of the invention the compound of formula (I) in the form of a granular solid which is readily filterable obtainable by a process comprising:

(a) oxidising of a solution of a compound of formula (II) in water/tetrahydrofuran with periodic acid in water at a temperature of around 20-30 °C; followed by

10 (b) precipitating the compound of formula (I) by addition of water at a temperature of around 22°C.


As a further aspect of the present invention we provide a novel process for the preparation of a compound of formula (A) which comprises the following step:



15 wherein step (a) comprises oxidation of a solution containing the compound of formula (II).

20 A preferred embodiment of the present invention is wherein the process for the preparation of a compound of formula (A) comprises the following steps:

6



wherein step (a) comprises oxidation of a solution containing the compound of formula (II).

5

Step (b) will typically comprise the addition of a reagent suitable for converting a carboxylic acid to a carbothioic acid eg. using hydrogen sulphide gas together with a suitable coupling agent eg. carbonyldiimidazole (CDI) in the presence of a suitable solvent eg. dimethylformamide.


10

Step (c) typically comprises the addition of a reagent suitable for performing the esterification to the ethyl ester eg. propionyl chloride in the presence of suitable solvents eg. diethylamine, triethylamine, dichloromethane and acetone. Step (d) typically comprises the addition of a reagent suitable for performing alkylation eg. either by direct conversion by addition of a haloalkyl compound or via an iodinated intermediate compound.

15

7

As a further aspect of the present invention we also provide a novel process for the preparation of a compound of formula (B) which comprises the following step:




5

wherein step (a) comprises oxidation of a solution containing the compound of formula (II).

10


A preferred embodiment of the present invention is wherein the process for the preparation of a compound of formula (B) comprises the following steps:



wherein step (a) comprises oxidation of a solution containing the compound of formula (II).

Typical conditions for step (b) and (c) are as previously described. Typically, step (e) will comprise reagents suitable to effect the coupling of compounds of formula (IV) with compounds of formula (V) eg. in the presence of a suitable solvent eg. dimethylformamide together with a suitable base eg. 2,4,6-collidine, pyridine or caesium carbonate. Compounds of formula (B) may then be optionally purified by suitable recrystallisation processes eg. recrystallisation from suitable solvents eg. isopropanol, diethylketone or methyl isobutyl ketone.

Compounds of formula (V) may be prepared according to the following process:




wherein step (i) typically comprises the addition of a suitable reagent eg. methanesulphonyl chloride in the presence of solvents eg. triethylamine, dimethylaminopyridine and ethyl acetate.

In step (e), analogues of compounds of formula (V) in which the MsO-group is replaced with another leaving group may also be employed.


It will be understood that this novel process makes use of an alternative starting material, flumethasone (formula (II)). Surprisingly, it has been shown that the use of such a starting material in the process for preparing fluticasone propionate and 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -

propionyloxy-androsta-1,4-diene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester would substantially reduce production costs for these steroids.


5 As a further aspect of the present invention we also provide the use of a compound of formula (II):



in the preparation of a compound of formula (I):




As a further aspect of the present invention we also provide the use of a compound of formula (II):




in the preparation of a compound of formula (A):


10



As a further aspect of the present invention we also provide the use of a compound of formula (II):



5 in the preparation of a compound of formula (B):



The present invention is illustrated by the following Examples:

Intermediate 1: 6 α , 9 α -difluoro-11 β , 17 α -dihydroxy-16 α -methyl-3-oxoandrosta-1,4-diene-17 β -carbothioic acid

A solution of Example 1 (12.0g) in dry dimethylformamide (250ml) was stirred and treated with N,N'-carbonyldiimidazole (9.94g) under nitrogen at room temperature. After 4 hours, hydrogen sulphide was passed through the solution for 0.5 hours. The reaction mixture was poured into 2M hydrochloric acid (500ml) containing ice (approximately 250g). The resulting precipitate was collected, washed with water and dried in vacuo to give the title compound as a white solid (11.47g), m.p. 230-232°C, $[\alpha]_D +94^\circ\text{C}$ (c 0.91).

Intermediate 2: 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-17 β -carbothioic acid

A solution of Intermediate 1 (5.0g) and triethylamine (6.15ml) in dichloromethane (140ml) was cooled with ice-salt and treated dropwise with propionyl chloride (4.74ml). The reaction mixture was stirred further at approximately 0°C for 0.75 hours then washed successively with 2M sodium carbonate, water, 2M hydrochloric acid, water and brine. After being dried, solvent was removed to give a white solid (6.35g). This was redissolved in acetone (120ml) and diethylamine (12.5ml): after being stirred at room temperature for 1 hour the volume was reduced to approximately 75ml. The solution was poured into 2M hydrochloric acid (200ml) containing ice (approximately 300g) and the resulting precipitate was collected, washed with water and dried in vacuo to a white solid (5.17g) m.p. 152-155°C. Recrystallisation of a portion (400mg) from ethyl acetate gave the analytically pure title compound as colourless crystals (290mg), m.p. 161-164°C, $[\alpha]_D -27^\circ\text{C}$ (c 0.95).

Intermediate 3: Methansulfonic acid 2-oxo-tetrahydro-furan-3R-yl ester

Triethylamine (1.5vol, 1.1eq) and 4-N,N-dimethylaminopyridine (0.012wt, 0.01eq) in ethylacetate (2vol) is added to a stirred solution of (R)-(+)- α -hydroxy- γ -butyrolactone (1wt, 1eq) in ethyl acetate (12vol) under nitrogen at 20°C \pm 3°C.

The solution is cooled to below 10°C and methanesulphonyl chloride (0.79vol, 1.05eq) is cautiously added to the reaction mixture over a period of at least 15 minutes at a rate sufficient to maintain the reaction temperature below 35°C. After complete addition, the reaction mixture is cooled to 20°C +/-3°C and stirred for up to 7h at 20°C +/-3°C under nitrogen, monitoring for completion by TLC (EtOAc, cyclohexane; 1:1; staining solution: 3g KMnO₄, 20g K₂CO₃, 0.5g NaOH, and 300ml water) or GC. Upon completion, the reaction mixture is treated with 1M HCl (3vol) and stirred until all solids have dissolved. The phases are separated and the organic phase is washed with further 1M HCl (3vol). The phases are separated and the organic phase is distilled under reduced pressure to approximately 4vol using a rotary evaporator. The organic solution is heated to 40-50°C and treated with cyclohexane (12vol). The mixture is cooled to below 15°C and aged at 10-15°C for at least 15 minutes. The mixture is filtered, the collected solid is washed with cyclohexane (2x3vol) and dried under vacuum at 30-35°C to yield the title compound as a white solid. Expected yield: 150%w/w, 85%theory.

Example 1: 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -hydroxy-androsta-1,4-diene-17 β -carboxylic acid

A suspension of flumethasone (40g) in tetrahydrofuran (199ml) was treated with lab grade water (13.2ml) and stirred at 20°C until a clear solution was achieved (approximately 2 minutes). The solution was cooled to less than 10°C and an aqueous solution of periodic acid (99% purity, 33.32g (1.5mole equivalents) in water (68ml)) was added dropwise over a period of 6 minutes. The clear solution was allowed to warm to ambient (approximately 20°C) and stirred at ambient for 2 hours and 5 minutes. HPLC analysis at 90minutes showed 97.4area% title compound present in the reaction mixture. Water (1000ml) was added dropwise over a period of 15 minutes causing crystallisation/precipitation of the product. After complete addition, the mixture was externally cooled and aged at approximately 10°C for 100minutes and the product filtered off. The bed was

washed with water (3x140ml) and dried at 70°C (house vacuum) for 26 hours and 40 minutes leaving the title compound as a white granular solid (37.98g, 98.3%th).

5 Example 1A: 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -hydroxy-androsta-1,4-diene-17 β -carboxylic acid

A suspension of flumethasone (5g, 12.2mmol) in dioxan (22ml) and lab grade water (3ml) was treated with an aqueous solution of periodic acid (50%w/w purity, 6.65g, 14.6mmol (1.2mole equivs)) over a period of 45 minutes keeping
10 the temperature in the range 25-30°C. The suspension was stirred at ambient for 2 hours. HPLC analysis at near 2 hours showed 98.1area% title compound present in the reaction mixture. Water (70ml) was added dropwise over a period of 45 minutes. After complete addition, the mixture was stirred 20°C for 1 hour and the product filtered off. The bed was washed with water (2x15ml) and dried
15 at 60°C (house vacuum) for 18 hours leaving the title compound as a white granular solid (4.65g, 96.3%th).

Example 1B: 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -hydroxy-androsta-1,4-diene-17 β -carboxylic acid

20 A suspension of flumethasone (5g, 12.2mmol) in diethylene glycol dimethyl ether (22ml) and lab grade water (4.4ml) was treated with an aqueous solution of periodic acid (50%w/w purity, 6.65g, 14.6mmol (1.2mole equivs)) over a period of 45 minutes keeping the temperature in the range 25-30°C. The suspension was stirred at ambient for 5 hours. HPLC analysis at near 5 hours showed
25 95.8area% title compound present in the reaction mixture. Water (70ml) was added dropwise over a period of 45 minutes. After complete addition, the mixture was stirred at 20°C for 1 hour and the product filtered off. The bed was washed with water (2x15ml) and dried at 60°C (house vacuum) for 72 hours leaving the title compound as a white granular solid (4.66g, 96.5%th).

Example 1C: 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -hydroxy-androsta-1,4-diene-17 β -carboxylic acid

A suspension of flumethasone (5g, 12.2mmol) in tetrahydrofuran (22ml) and lab grade water (4.4ml) was treated with an aqueous solution of sodium periodate (99% purity, 3.13g, 14.6mmol (1.2mole equivalents)) in hydrochloric acid (12 molar, 1.46ml 17.5mmol (1.43 equiv)) and water (8.5ml) over a period of 30 minutes keeping the temperature in the range 25-30°C. The suspension was stirred at ambient for 2 hours. HPLC analysis at near 2 hours showed 98.4area% title compound present in the reaction mixture. Water (65ml) was added dropwise over a period of 20 minutes. After complete addition, the mixture was cooled to 10°C, was stirred at 20°C for 2 hours and the product filtered off. The bed was washed with water (2x15ml) and then dried at 60°C (house vacuum) for 18 hours leaving the title compound as a white granular solid (4.65g, 96.3%th).

Example 1D: 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -hydroxy-androsta-1,4-diene-17 β -carboxylic acid

A suspension of flumethasone (1weight) in tetrahydrofuran (4.4vol) and water (0.9vol) was stirred at 22+/- 3°C until a clear solution was achieved. An aqueous solution of periodic acid (50%w/w, 1.33 weights, 1.2equivalents) was added over approximately 45 minutes at a rate sufficient to maintain a reaction temperature of 25+/-5°C. A further portion of water (0.1vol) was added as a line wash and the mixture was stirred at 22+/-3°C for 2 hours (note, the hydroxyacid product starts to crystallise after approximately 1 hour of this stir period). Water (14vol) was added to the suspension over at least 30 minutes maintaining a reaction temperature in the range 22+/-3°C. The mixture was cooled to approximately 10 °C and stirred for at least 1 hour at this temperature. The solid was filtered off and the bed washed with water (2x3vol) at 22+/-5°C. The product was dried under vacuum at 60+/-5°C to afford hydroxyacid as a white granular solid (expected yield 97%th).

Example 2: 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-17 α -propionyloxy-3-oxoandrosta-1, 4-diene-17 β -carbothioic acid, S-fluoromethyl ester

The compound of Example 2 may be prepared from Intermediate 2 following the processes described in GB Patent No. 2288877B.

5

Example 3: 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester

A mixture of Intermediate 2 (1wt), Intermediate 3, and DMF (3.5vol) is treated with 2,4,6-collidine (0.268wt, 1.04eq). The resulting solution is heated at 39-43°C for approximately 4h until complete by HPLC. 2M Hydrochloric acid (0.2vol) is added and residual ethyl acetate is removed by vacuum distillation. The solution is warmed to 60°C and water (approximately 2vol) is added over 5-30 min at 60-65°C, seeding when a fine suspension has formed. The suspension is aged at 55-65°C for at least 5 min and water (approximately 8vol; total water added 10vol) is added slowly at 49-60°C. The suspension is allowed to cool to room temperature and is aged for at least 30min (typically overnight). The title compound is filtered off, washed with water (3 x 2vol), and pulled dry.

10

15

The title compound is then purified using isopropanol recrystallisation, which comprises heating to reflux a suspension of the title compound in isopropanol (13.4 vol) and holding at reflux for at least 5 minutes. (At this stage the reaction mixture may be given a hot filtration). The solution is heated and maintained above 60°C whilst filtered, purified water (5.6vol) is added dropwise over at least 10 minutes. The suspension is cooled to 0-10°C and then aged at <10° for at least 30 minutes. The solid is collected by vacuum filtration, washed with filtered purified water (2 x 3.4vol) and dried under vacuum using a filter bed for at least 15 minutes. The product is dried in vacuo at up to 70°C overnight. Expected yield: 99% w/w, 84% theory (uncorrected) from Intermediate 2.

20

25

The merits of the present invention may be seen by reference to the following Comparative Example:

Comparative Example

5 Example was prepared following a procedure analogous to that described in J. Med. Chem. (1994), 37, 3717, example 2b, (half scale), which describes conversion of des-16 alpha methyl dexamethasone to corresponding hydroxyacid via a cold isolation.

10 A suspension of flumethasone (5.42g, 13.2mmol) in tetrahydrofuran (27.5ml) and lab grade water (3ml) was treated with an solution of periodic acid (99% purity, 4.5g, 19.8mmol (1.5mole equivs)) in lab grade water (45ml) over a period of 15 minutes keeping the temperature in the range 20-30°C. The suspension was stirred at ambient for 2 hours and an essentially clear solution resulted.

15 HPLC analysis at near 2 hours showed 98.9area% title compound present in the reaction mixture. The reaction mixture was then added to a stirred mixture of water (75ml) and crushed ice (125g) over 5 minutes. The suspension was then stirred at 0-2°C for 10 minutes and the solid was filtered off to give a very volumous gel (ca100ml).

20

This comparative example resulted in a voluminous product with a high level of associated solvent and it was not possible to remove this solvent by conventional solvent removal techniques, such as low temperature filtration. By contrast, in Example 1A, 1B, 1C and 1D, the title compound was obtained in a

25 relatively low volume (ca 4 ml) as a granular solid in a form which was readily filterable. In Example 1 which was performed on a larger scale the same low volume solid was obtained (ca 32 ml).

30

Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and


'comprising', will be understood to imply the inclusion of a stated integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps.

- 5 The above mentioned patents and patent applications are herein incorporated by reference.

CLAIMS


1. A process for the preparation of a compound of formula (I) which comprises the following step:

5




wherein step (a) comprises oxidation of a solution containing the compound of formula (II).

2. A process for the preparation of a compound of formula (A):




10

which comprises the following step:




wherein step (a) comprises oxidation of a solution containing the compound of formula (II).

3. A process for the preparation of a compound of formula (A) according to claim 2 which comprises the following steps:




- 5 wherein step (a) comprises oxidation of a solution containing the compound of formula (II).

4. A process for the preparation of a compound of formula (B):




20

which comprises the following step:



5 wherein step (a) comprises oxidation of a solution containing the compound of formula (II).

5. A process for the preparation of a compound of formula (B) according to claim 4 which comprises the following steps:



10

wherein step (a) comprises oxidation of a solution containing the compound of formula (II).

6. A process according to any one of claims 1 to 5 wherein step (a) is performed in the presence of a solvent comprising methanol, water, tetrahydrofuran, dioxan or diethylene glycol dimethylether.

5 7. A process according to claim 6 wherein step (a) is performed in the presence of methanol, water or tetrahydrofuran as solvent.

8. A process according to claim 6 wherein step (a) is performed in the presence of water and tetrahydrofuran as solvent.

10

9. A process according to any one of claims 1 to 5 wherein the solution containing the compound of formula (II) is cooled prior to oxidation eg. to a temperature less than approximately 10°C.

15

10. A process according to any one of claims 1 to 9 wherein the oxidation step comprises the use of a chemical oxidising agent.

11. A process according to claim 10 wherein the oxidising agent is periodic acid or iodic acid or a salt thereof.

20

12. A process according to claim 11 wherein the oxidising agent is periodic acid or sodium periodate.


25

13. A process according to claim 12 wherein the oxidising agent is periodic acid.


14. A process according to any one of claims 1 to 5 wherein the oxidation step comprises an oxidation reaction which utilises air and/or oxygen.

15. A process according to claim 14 wherein the solvent used in said reaction is methanol.
- 5 16. A process according to any one of claims 1 to 5 wherein step (a) is incubated at room temperature.
- 10 17. A process according to any one of claims 1 to 16 which further comprises a step (b) of precipitation of the compound of formula (I) in crystalline form from the reaction mixture by addition of an anti-solvent under temperature conditions of around 10 °C or higher.
18. A process according to claim 17 wherein the anti-solvent is water.
- 15 19. A process according to claim 17 or claim 18 wherein the temperature of step (b) is around ambient temperature or higher.
- 20 20. Compound of formula (I) in the form of a granular solid which is readily filterable obtainable by a process comprising:
(a) oxidising of a solution of a compound of formula (II) in water/tetrahydrofuran with periodic acid in water at a temperature of around 20-30 °C; followed by
(b) precipitating the compound of formula (I) by addition of water at a temperature of around 22°C.
- 25 21. Use of a compound of formula (II):


23



in the preparation of a compound of formula (I):




22. Use of a compound of formula (II):




5

in the preparation of a compound of formula (A):




24

23. Use of a compound of formula (II):



in the preparation of a compound of formula (B):



INTERNATIONAL SEARCH REPORT

Application No

PCI/GB 01/03289

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07J5/00 C07J31/00 C07J3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PHILLIPPS G H ET AL: "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS IN A SERIES OF ANTIINFLAMMATORY CORTICOSTEROID ANALOGUES, HALOMETHYL ANDROSTANE-17BETA-CARBOTHIOATES AND-17BETA-CARBOSELENOATES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 22, 1 October 1994 (1994-10-01), pages 3717-3729, XP002025925 ISSN: 0022-2623	1-3, 6-13, 16-22
Y	page 3717, column 2, paragraph 2 page 3724, column 1, line 56-63 page 3724, column 2, line 50-62 page 3726, column 2, line 38-60 --- -/--	4,5,23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

29 October 2001

Date of mailing of the international search report

09/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Watchorn, P

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 01/03289

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KERTESZ, DENIS J. ET AL: "Thiol esters from steroid 17.beta.-carboxylic acids: carboxylate activation and internal participation by 17.alpha.-acylates" J. ORG. CHEM. (1986), 51(12), 2315-28 , XP002181480 page 2323, column 2, paragraph 2	1,6-13, 16-21
L	this document is explicitly referred to as the source of the compound 2e used in the synthesis of compound 5c in above document XP2025925, see page 3724, col 1, lines 56-63 of XP2025925	1-3, 6-13, 16-22
X	DE 19 64 356 A (CIBA AG) 2 July 1970 (1970-07-02) example 1	1,6-13, 16-21
X	US 4 198 336 A (ALVAREZ FRANCISCO S) 15 April 1980 (1980-04-15) example 2	1,6-9, 14-21
X	GB 2 018 256 A (SYNTEX INC) 17 October 1979 (1979-10-17) page 5, line 56 -page 6, line 7	1,6-9, 14-21
X	WO 95 18621 A (UNIV DUKE) 13 July 1995 (1995-07-13) example 4	1,6-13, 16-21
Y	WO 97 24365 A (GLAXO GROUP LTD ;BIGGADIKE KEITH (GB); PROCOPIOU PANAYIOTIS ALEXAN) 10 July 1997 (1997-07-10) examples 1,2	4,5,23
E	WO 01 62722 A (ABBOTT LAB) 30 August 2001 (2001-08-30) examples 1-4	1,2, 6-13, 16-22

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/GB 01/03289

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 1964356	A	02-07-1970	BE 743546 A DE 1964356 A1 FR 2026919 A1 NL 6919212 A US 3636010 A	22-06-1970 02-07-1970 25-09-1970 25-06-1970 18-01-1972
US 4198336	A	15-04-1980	NONE	
GB 2018256	A	17-10-1979	US 4188385 A AR 226035 A1 AT 368168 B AT 251979 A AU 526025 B2 AU 4558379 A CA 1134345 A1 CS 203956 B2 DE 2912331 A1 DE 2960096 D1 DK 136579 A ,B, EP 0004741 A2 ES 479271 A1 FI 791081 A ,B, FR 2421912 A1 GR 67275 A1 HK 41284 A HU 179314 B IE 48369 B1 IT 1120954 B JP 1338662 C JP 54141758 A JP 61001038 B JP 1374793 C JP 60069019 A JP 61040648 B MY 57585 A NO 791140 A ,B, NZ 190076 A PL 214676 A1 PT 69409 A SG 6786 G SU 1052161 A3 US 4263289 A YU 80379 A1 ZA 7901635 A	12-02-1980 31-05-1982 27-09-1982 15-01-1982 16-12-1982 18-10-1979 26-10-1982 31-03-1981 18-10-1979 19-03-1981 06-10-1979 17-10-1979 16-01-1980 06-10-1979 02-11-1979 26-06-1981 18-05-1984 28-09-1982 26-12-1984 26-03-1986 29-09-1986 05-11-1979 13-01-1986 22-04-1987 19-04-1985 10-09-1986 31-12-1985 08-10-1979 31-07-1984 02-01-1980 01-04-1979 01-08-1986 30-10-1983 21-04-1981 30-04-1983 26-11-1980
WO 9518621	A	13-07-1995	US 5646136 A AU 696678 B2 AU 1598895 A CA 2180325 A1 EP 0742718 A1 JP 9511485 T WO 9518621 A1	08-07-1997 17-09-1998 01-08-1995 13-07-1995 20-11-1996 18-11-1997 13-07-1995
WO 9724365	A	10-07-1997	AT 194356 T AU 721865 B2 AU 1140997 A BG 102625 A BR 9612309 A	15-07-2000 13-07-2000 28-07-1997 30-04-1999 13-07-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/03289

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9724365	A	CA 2241728 A1	10-07-1997
		CN 1209135 A	24-02-1999
		CZ 9802074 A3	11-11-1998
		DE 69609199 D1	10-08-2000
		DE 69609199 T2	01-03-2001
		DK 876392 T3	06-11-2000
		EE 9800227 A	15-12-1998
		EP 0876392 A1	11-11-1998
		ES 2150150 T3	16-11-2000
		WO 9724365 A1	10-07-1997
		GR 3034564 T3	31-01-2001
		HU 9903707 A2	28-03-2000
		JP 2947944 B2	13-09-1999
		JP 11501675 T	09-02-1999
		NO 983004 A	26-08-1998
		NZ 324373 A	28-10-1999
		PL 327629 A1	21-12-1998
		PT 876392 T	29-12-2000
		SI 876392 T1	31-12-2000
		SK 89198 A3	10-03-1999
		TR 9801247 T2	23-11-1998
		US 6197761 B1	06-03-2001
WO 0162722	A	30-08-2001	WO 0162722 A2
			30-08-2001